Treatment and follow-up
pStage [stage IA (T1bN0M0)/IB or IIA/IIB, tumor, comorbidity
SQUAMOUS CELL CARCINOMA, THORACIC, CARCINOMA, TUMOR
The principal investigator/participating investigator confirmed that the eligible patients met all the eligibility criteria and did not violate the exclusion criteria, filled out the “Case Registration Form”, and faxed the form to the research secretariat (Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan). After the research secretariat confirmed eligibility, it faxed back a notification of case registration results to the investigator. Upon enrollment, each patient was randomly assigned to a treatment by Dr. Keitaro Matsuo, Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka, Japan. Random assignment was performed using a minimization method with the following adjustment factors: pStage [stage IA (T1bN0M0)/IB or IIA/IIB or IIIA], histology (squamous cell carcinoma or non-squamous cell carcinoma), epidermal growth factor (As for baseline evaluations, medical history, smoking history, physical examination, operation date, p-TNM status, tumor histology (squamous cell carcinoma or non-squamous cell carcinoma), comorbidity, and laboratory analyses were included. The details of the follow-up assessments are provided in 